Effect of chronic lithium treatment upon the Na+-coupled cotransporters in renal brush border membranes  by Yusufi, Ahad N.K. et al.
Kidney International, Vol. 43 (1993), pp. 1074—1080
Effect of chronic lithium treatment upon the Natcoupled
cotransporters in renal brush border membranes
AHAD N.K. YusuFI, STEN CHRISTENSEN, and THOMAS P. DOUSA
Nephrology Research Unit, Division of Nephrology and Internal Medicine, Departments of Medicine and Physiology, Mayo Clinic and
Foundation, Mayo Medical School, Rochester, Minnesota, USA
Effect of chronic lithium treatment upon the Na-coupIed cotransport-
ers in renal brush border membranes. While the most frequent and
prominent side effect of the chrome lithium (Li) administration is
dysfunction of collecting ducts and polyuric syndrome, some reports
also suggest defects in functions of proximal tubules. We determined
the transport properties of brush border membranes (BBM) from
kidneys of rats chronically fed for four weeks a chow containing Li (60
mmol/kg; Li-rats) and compared them with BBM from placebo-treated
controls. BBM from Li-rats did not differ from controls in Na-
gradient-dependent transport of 32Pi, D-[3H]-glucose or L-[3H1-proline,
but showed a considerable increase in the transport rates of ['4C]-citrate
(z + 53%; P < 0.001) and ['4C1-succinate ( + 48%, P < 0.005), and
also enhanced the rate of Na-H antiport across BBM ( + 30%, P <
0.05). In contrast, direct addition of 1 ms'i Li to BBMV in vitro inhibited
Na-dependent transports of both citrate and succinate. The Li-rats
had higher plasma level of citrate and decreased ( — 50%) renal
clearance of citrate. Our results show that chronic exposure to oral Li
in vivo results in increased Natgradientdependent transport of poly-
carboxylic acids and increased Na-H antiport in BBM of proximal
tubules; these changes are contrary to effects of Li added to isolated
BBM in vitro.
The functional impairments of distal nephron segments,
namely vasopressin-resistant decrease in urinary concentrating
ability [1, 2] and a mild acidification defect [3], are the most
frequent consequences of chronic oral lithium (Li) administra-
tion. However, several observations suggest that Li may also
cause pathophysiologic changes in the proximal tubules, a part
of the nephron where 80% or more of the filtered Li is
reabsorbed [11. The observations pointing to possible effects of
Li on the proximal tubules are all based either on studies
examining acute or subacute administration of Li in vivo [4—6],
or on findings of Li effects upon transport in vitro [7—111.
Hecht et al [4] observed in a micropuncture study that
infusion of Li (plasma Li 2 to 3 mM) was followed by reduced
reabsorption of fluid and solutes in the proximal nephron.
Wright et at [8] described that direct addition of Li to isolated
rabbit renal brush border membrane vesicles (BBMV) caused
inhibition of the Na-gradient-dependent uptake of ['4C]-succi-
nate (Ki = 1.3 mM) and ['4C]-citrate, and to a lesser degree, also
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inhibition of BBMV uptake of D-glucose and L-phenylalanine
[8]. According to several reports, when added directly in vitro
to rabbit BBMV, Li inhibits the amiloride-sensitive Na-H
antiport [9—111.
According to another report [71, incubation of renal cortical
slices in a medium containing Li (0.3 to 2 mM) decreased the
uptake of p-amino hippurate (PAH). Subsequent study from the
same laboratory has shown that infusion of Li decreases
clearance of PAH and the uptake of PAH by renal cortical slices
from rats treated four days with Li was blunted [6]. Finally,
after a 12 day administration of Li to rats, Bond and Jenner [5]
observed increased renal output of a-ketoglutarate and citrate
[5]. While results of these studies indeed suggest that Li can
alter proximal tubular functions, these experimental conditions
are quite remote from chronic oral consumption of relatively
small amounts of Li, as it is used in the management of the
manic-depressive syndrome.
In view of these considerations, we set out to determine
effects of Li under conditions which closely resemble chronic
treatment with Li in humans [12, 13—15]. In this model, Li is
administered to rats orally for at least several weeks in solid
food simultaneously with ad libitum access to drinking of 0.9%
NaCl. This regimen keeps plasma levels of Li in the therapeutic
range (< 1 mM Li), prevents intermittent sharp increases in
plasma Li and prevents salt depletion which leads to acute Li
nephrotoxicity [13, 14, 16]. We examined whether this chronic
Li treatment influences one of the key cellular components of
transport across proximal tubules: the Na-gradient coupled
cotransporters in the luminal brush-border membrane (BBM).
The results of our studies document that such chronic treatment
with Li selectively alters several Na-cotransporters in renal
BBM, and moreover, that these changes are opposite to the in
vitro effects of acute Li addition to isolated BBM [8—11].
Methods
Experiments were conducted on adult male albino rats of
either the Sprague-Dawley or Wistar strains, both purchased
from Charles River Breeding Laboratories (Wilmington, Mas-
sachusetts, USA). Since results of the studies on these two
strains of rats were identical, data are presented interchange-
ably. The rats were kept in an air conditioned room (21° to 25°C)
with a free access to (free choice to drink) both distilled water
and a solution of 0.9% NaC1 [2, 12, 13].
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Experimental design
As a general rule, rats treated with Li (referred to from here
on as Li-rats) and the corresponding controls were always
handled and analyzed using paired design 12, 17, 18]. The
control and Li-rats entered, completed the treatment regimen,
and were sacrificed on the same day, and the blood, urine and
kidney cortex were collected and analyzed simultaneously [2,
17—19].
Typically, four to six rats, weighing 200 to 230 g, were
entered into the protocol as a control group (2 to 3 rats, which
received standard chow diets) and as an experimental group
(also 2 to 3 rats, which received the same chow but with added
Li to the final content of 60 mmol/kg dry weight) [2, 12, 131. The
Li containing diet was prepared by adding 1 M LiCl and an
approximate amount of water to powdered standard chow to
give wet mesh, which was subsequently dried in the oven at
60°C [2].
Intake of fluids, distilled water and 0.9% NaCI solution was
recorded for four days within one week and the body weight
once a week. After 24 days, the rats were placed in individual
metabolic cages and the urine was collected between 9 a.m. and
12 a.m. [2, 181. After a total period of 26 to 29 days of the
dietary regimen, the rats (control and Li-rats) were anesthetized
with intraperitoneal pentobarbital and a sample of blood was
taken from the jugular vein. The kidneys were rapidly removed
and chilled in ice-cold buffered saline pH 7.4 for preparation of
brush-border membrane vesicles (BBMV).
Preparation of BBMV and the transport studies
BBMV were prepared from homogenized renal cortical tissue
by the slightly modified calcium precipitation procedure de-
scribed in full in our previous studies on rats [17—20]. As a final
step, the BBMV were washed with 300 m mannitol, 5 mM
Tris-Hepes (pH 8.5) and were used immediately for transport
studies. Preparation of BBMV, measurements of transport, and
determinations of marker enzymes were conducted simulta-
neously on control and corresponding Li-rats, using the same
standards and reagents.
The uptakes of 32Pi, L-[3H1-proline, D-[3H]-glucose, ['4C]-
citrate and ['4C]-succinate was measured by the Millipore
filtration technique [17—21]. Briefly, BBMVs (— 0.1 mg of
protein) were suspended in a medium containing 100 mM
mannitol, 100 mi NaCl, 5 mrvi Tris-Hepes (pH 8.5) and either
0.1 mri K2H32P04 or 0.05 mt D-[3H]-glucose, 0.025 mM
L-[3H]-proline and 0.1 m ['4C]-citrate or 0.1 mM ['4C]-succi-
nate (final concentrations). The uptake was measured at 20°C
and was terminated at various time periods (Results) by the
addition of ice-cold 135 mM NaCl, 10 m arsenate, and 5 mM
Tris-Hepes (pH 8.5).
The rate of Na-H exchange (antiport) was determined by
using a rapid filtration technique as described previously [17,
201. When the Na-H exchange across BBMV was measured,
BBMV were prepared identical to BBMV for other solute
uptake studies [17—21], but were preloaded by resuspending and
washing the BBMV in an acidic medium containing 150 mM
KC1, 25 mri 2-(N-morpholino)-ethanesulphonic acid (MES) and
4.6 mM Tris, adjusted with KOH to pH 6.0 [17, 20]. The rate of
Na-H exchange was measured by incubation of BBMV
preloaded with acidic intravesicular medium in a medium
containing 144 mM KC1, 5 m MES, 13 mM Tris and 13 mM
Hepes, adjusted with KOH to pH 7.5 and containing 1 mM
22NaCl (0.2 Ci of 22Na per tube) in a final volume of 45 d.
The incubation was terminated by addition of 3 ml of ice-cold (0
to 2°C) stop solution containing 150 mrvi KC1, 16 mrvi Hepes and
10 mM Tris, adjusted with KOH to pH 7.5 and rapid filtration
[14, 17] similar to other transport studies [14—18]. The 22Na
uptake at pH gradient condition (pH1 < pH0) was always
measured simultaneously with and without addition of 1 mM
amiloride, the maximum inhibitory concentration of the com-
pound [201.
The rate of uptake of all solutes as well as the Na-H
exchange rate were expressed in picomoles of solute/mg of
BBMV protein per given time interval. In each BBMV prepa-
ration, the uptake of solutes was measured in quadruplicate at
each time period and the mean SE was entered as N = 1.
Protein was measured by the method of Lowry et al [22] after
solubilization of the samples in 0.5% sodium dodecyl sulfate,
and in our previous studies [17—21].
Other analytical methods
Activities of BBM marker enzymes, that is, alkaline phos-
phatase, y-glutamyltransferase and leucine amino-peptidase
were assayed by calorimetric methods previously used in
studies in this laboratory [17—20]. All enzyme activities were
measured under conditions in which the enzyme reaction rates
were linear with respect to incubation time and protein concen-
trations. There was no difference in the activities of marker
enzymes between control and Li-rats, and the BBMV prepara-
tions showed the similar enrichment compared to cortical
homogenates in both type of rats.
Plasma and urinary citrate were measured enzymatically [21,
23]; pH, pCO2 and HCO in samples of central venous blood
were measured with a blood gas analyzer (Instrumentation
Laboratory, Lexington, Massachusetts, USA). Plasma lithium
was determined by flame emission spectrophotometry, alter
precipitation of proteins with 5% trichloroacetic acid [2].
The results were evaluated statistically by Student's t-test for
groups or paired comparisons as specified in the Results. Values
of P> 0.05 were considered not significant (NS).
Results
The model of chronic oral lithium administration of about
four weeks duration was designed to approximate pathophysi-
ologic consequences of chronic administration of lithium salts
in the clinical setting [2, 22, 23]. Indeed, using this regimen rats
developed polyuric syndrome while the plasma levels of Li
remained within the range of values (< 1 mM), which are
considered within therapeutic range (The term "therapeutic"
denotes values considered sale and effective in chronic clinical
treatment of manic-depressive syndrome.) (Table 1).
The capacity for Na-cotransport of several distinct solutes
by BBMV prepared from Li-rats showed specific alterations as
compared to controls (Fig. 1). While the Na-gradient (Na0 >
Na1)-dependent concentrative uptakes of 32Pi, D-[3H]-glucose
and L-[3H]-proline were not significantly different between
BBMV from Li-rats and the controls, the Na-gradient-depen-
dent concentrative uptake of ['4C]-citrate and ['4C]-succinate
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Table 1. Blood, plasma and urine parameters from the control rats
and Li-treated rats at the end of the experiments
Parameters Control Li-treated P value
Plasma Li mi ND 0.54 0.05a
Blood pH 7.39 0.01 7.36 0.02 NS
Blood creatinine M 55.7 3.5 54.8 2.6 NS
Plasma citrate M 155 7 185 10 <0.02
Urine citrate pnol/ 5.55 1.0 4.23 1.1 NS
100 g body wt/hr
Citrate clearance 27.9 1.5 13.9 2 <0.001
ml/100 g body
wt/hr
Urine flow 0.38 0.06 2.43 0.46 <0.001
ml/100 g body
wt/hr
Significance of difference was determined by t test. Abbreviation ND
is not detectable.
Values denote mean SEM for 5 to 14 experiments
were markedly (cca + 40 to 60%) enhanced in BBMV from Li
rats (Table 2, Fig. 1). There were no significant differences in
uptakes of any of these solutes in the absence of Nat-gradient
(NaCl replaced by KC1), and also the uptakes of 32Pi, L-[3H}-
proline, D-[3H]-glucose [14C]-citrate or ['4C}-succinate at equi-
librium point (120 mm) were not statistically different (Table 2).
The uptake of solutes at the equilibrium point tended to be
slightly higher in Li-rats (Table 2). When the Na-gradient
dependent uptake of [14C]-citrate was re-examined in another
experimental group (Table 3A), these results affirmed that in
BBMV from Li-rats the Na -dependent concentrative uptake
of ['4C]-citrate was markedly increased, whereas at equilibrium
time (120 mm) the uptake was not significantly enhanced. The
finding of no significant differences in the Na-gradient-depen-
dent uptakes of 32Pi-phosphate, L-[3H}-proline and D-[3H1-
glucose between Li-treated and control animals also indicates
that the higher rate of uptake of ['4C]-citrate and ['4C]-succinate
cannot be accounted for by changed conductance of Na in
BBM and the higher efficiency of the (Na0 > Na)-gradient as
driving forces in Li-rats (Table 2, Fig. 1). To test whether direct
addition of Li to BBMV in vitro inhibits ['4C]-citrate uptake [8],
the Natdependent [14C]-citrate uptake was determined on
BBMV preparations from control rats (not treated chronically
with Li; Table 3A) after in vitro addition of 1 mrs Li (Table 3B).
Similarly to BBMV from rabbit kidney [8], direct addition of Li
in vitro resulted in the inhibition of both Nat-gradient depen-
dent uptakes of ['4C]-citrate and ['4C]-succinate by rat BBMV
(Table 3B).
BBMV from Li-treated rats also showed increased capacity
for Na-H antiport (Fig. 1, Table 4), determined as 22Na
uptake in the presence of outwardly directed (pH1 < pH0)
proton gradient and sensitive to inhibition by amiloride [9—11,
17, 19] in the initial phases (0 to 30 sec) of the uptake where the
22Na uptake increased proportionally to elapsed time. How-
ever, no significant difference was observed between control
BBMV and BBMV from Li-rats in the initial phases (10 to 30
sec) of uptake of 22Na insensitive to amiloride; also, uptake of
22Na uptake at the equilibrium (110 mm) did not differ between
BBMV from kidneys of controls and from Li-rats (Table 4A).
Identical results were obtained in another series of experiments
(Table 4B) when the parameters were measured at different
initial (15 see) and equilibrium (90 mm) phases.
In order to discern whether increased activity of Na-citrate
and Natsuccinate contransporters in Li-rats had impact on
renal handling of citrate in vivo, we determined, at least
approximately, several parameters of renal citrate excretion
measured and/or calculated from other values (Table 1). The
Li-rats had significantly increased plasma citrate ( + 20%), no
significant difference in the total urinary citrate excretion
x V), and about —50% lower renal clearance of citrate (Table
1). On the other hand, plasma creatinine and plasma pH did not
differ between Li-rats and controls.
Discussion
The most prominent renal side effects of chronic oral treat-
ment with Li include the well-known polyuric syndrome resis-
tant to vasopressin [1, 2], the relatively mild distal renal
acidification defect [3], as well as ultrastructural injury in distal
segments of tubules [14]. Nevertheless, several observations
[4—11] prompted us to inquire whether the functions of cortical
proximal tubules may also be affected due to chronic oral
administration of Li. Thus, we examined the effects of chronic
exposure of Li on the function of several Na-coupled trans-
porters in the proximal tubular of BBM, which represent
rate-limiting steps in the transepithelial proximal reabsorption
of several key solutes.
No change in the capacity for NatPi cotransport across
BBM corresponded well to the reports which show that admin-
istration of Li does not alter the urinary excretion of Pi [24, 25].
Wright et al [8] reported that Li added in low concentrations in
vitro to BBMV inhibits Na-dependent cotransport of polycar-
boxylic acids across rabbit BBM; this led us to also determine
the Natcotransports of citrate and succinate in our model.
We confirmed that direct addition of Li in vitro indeed causes
inhibition of Na-cotransports of citrate and succinate in the rat
BBMV, and hence, is not species-specific (Table 3B). Direct
addition of 1 mt Li to BBMV from normal (control) rats caused
marked inhibition of Na-['4C]-citrate uptake (
—40%), and
to a lesser degree inhibition of [14C]-succinate (i
—17%)
uptake; the equilibrium uptakes were not affected (Table 3B).
However, in contrast to the direct effects of in vitro added Li
(Table 3B, [8]), in BBMV from Li-rats the capacity for Nat
gradient dependent uptakes of citrate and succinate were sig-
nificantly enhanced (Tables 2 and 3A, Fig. 1). These alterations
were specific, as compared to finding no significant changes in
other solute-specific Na1-cotransporters within the same
BBMVs (Table 2). Similarly, in previous studies [9—11] direct
addition of Li was reported to inhibit Na-H antiport across
rabbit BBM. Chronic exposure of BBM to Li in vivo elicited
change in the opposite direction: the increase in capacity for
Na-H antiport in BBMV from Li-rats (Fig. 1, Table 4).
The enhanced uptakes of [14C]-citrate and ['4C]-succinate
cannot be explained by increased driving force, since in the
same preparations of BBMV, the (Na0 > Na,)-dependent
uptakes of other solutes, such as 32P1, D-[3H]-glucose and
L-[3H]-proline, did not significantly increase. Closer examina-
tion of the results suggest that the uptake of solute equilibrium
(120 mm) and, by implication intravesicular volume of BBMV,
tends to be higher in the BBMV from Li-rats, albeit the
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difference did not reach statisticaly significance (Tables 2, 3 and
4). However, even if the slight increase in intravesicular volume
of BBMV from Li-rats could have contributed to higher rate of
uptake of solutes in general, the results show (Tables 2, 3A and
4) that increases of Natcitrate and Na-succinate uptakes, as
well as the NatH exchange in BBMV from Li-rats, cannot be
accounted for solely or predominantly by higher intravesicular
volume. (It should be noted that any increase of volume of
sphere changes as a cubic function of diameter, whereas the
surface changes as a quadratic function of diameter. Therefore,
increase in volume has far lesser impact upon the increase of
surface, that is, transporting membrane.)
Comparison of our observations (Tables 1 to 3, Fig. 1) with
reported effects of Li salts administered in vivo on renal
excretion should be briefly considered. Bond and Jenner [5]
reported increased total urinary excretion of citrate (the clear-
ances were not measured) after so-called "chronic" adminis-
tration of Li. However, in their experiments the citrate excre-
tion was measured after only 12 days of LiCl intake, and plasma
levels of Li and citrate were not reported [5]. Consequently,
their results are not amenable for any meaningful comparison
with results of our present studies, which were conducted using
a different experimental design.
The model of renal changes consequent to chronic Li treat-
ment employed in our study was intentionally developed to
approximate, as closely as possible, the situation occurring in
clinical chronic treatment of manic-depressive disorders with Li
salts [12—15]. Previous studies documented that functional [13]
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Fig. 1. (Na0 > Na1) -gradient-dependent uptake of various solutes by BBMV as well as Na4-H antiport across BBM: comparison of controls(0) and Li-treated () rats. Each bar denotes the mean SEM from N =4 to 9 experiments. For Na-H antiport values the mean SCM is based
on N = 3 experiments. BBMV from the control rats (C), and from the rats treated with lithium (Li) were tested and compared on paired basis.
Asterisk (*) denotes values significantly different from controls (paired t-test, P < 0.05 or higher degree of significance).
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Table 2. (Na0 > Nat) gradient-dependent (NaC1 in medium) and Na-independent (KC1 in medium) uptake of solutes by the renal brush
border vesicles (BBMV) from control rats and rats subjected to chronic Li treatment (Li-rats)
Solutes
Time
mm N Control Li-treated
P
valuea %b
Na1-citrate (NaCl in medium) 1
2
120
(9)
(8)
(9)
163 12
198 13
114 6
250 16
329 25
152 7
<0.001
<0.001
<0.005
+ 53%
+ 66%
+ 33%
K-citrate (KCI in medium) 120 (4) 54 3 68 4 NS
Na-succinate (NaCl in medium) 0.25
0.5
120
(7)
(8)
(8)
189 16
224 1489 7
280 20
322 21
107 5
<0.005
<0.005
NS
+ 48%
+ 44%
K-succinate (KCI in medium) 120 (5) 80 6 94 7 NS
Natphosphate (NaC1 in medium) 0.5
120
(9)
(9)
1584 95
586 26
1632 97
656 19
NS
NS
K-phosphate (KCI in medium) 120 (9) 155 12 192 30 NS
Na-pro1ine (NaCl in medium) 0.25
120
(7)
(7)
261 11
27 3
298 14
32 3
NS
NS
K-pro1ine (NaCI in medium) 120 (2) 38 1 47 I NS
Na-glucose (NaCl in medium) 0.25
120
(4)
(4)
399 25
60±4
449 42
67±5
NS
NS
Ktglucose (KC1 in medium) 120 (2) 62 1 73 2 NS
All transport rates are in pmollmg protein. For details see Methods. Number in parentheses (N) denotes the number of paired experiments. NS
is not significant.
a Significantly different from controls (paired 1-test)b Relative difference from controls
Table 3A. Comparison of Na-citrate uptake from control and
chronically Li-treated rats
Time
mm N Controls Li-treated %
Na-citrate 1 3 191 l3 270 19b (42 4)C
120 3 117 9 132 14" (12 4)
a Number of paired experimentsb Significantly different from controls (paired 1-test, P < 0.02)
C Relative (percent) increase significant (paired 1-test, P < 0.01); also
significantly different from value at 120 mm (group 1-test; P < 0.05)d Not significantly different from controls either by paired or group
t-tests
and histochemical [14] changes develop fully only after four
weeks of Li regimen. However, future time-course studies
could determine at which time interval within the four week
course of Li administration the observed changes in BBMV
Na-cotransporters do develop.
Our findings of increased capacity of Nat-citrate cotransport
across proximal tubular BBM in the rat kidney consequent to
chronic oral treatment with Li, seems to be reflected in renal
parameters of citrate dynamics observed in vivo (Table 1).
Similarly, as reported previously by Mellerup eta! [26], chronic
administration of Li to rats caused about a 20% increase in
plasma citrate. No difference in plasma creatinine suggests no
difference in GFR between Li-rats and controls (Table 1). We
thus suggest, very guardedly, that the decreased renal clearance
of citrate, which occurred despite an increased filtered load, is
likely due to the increased capacity of Na-citrate cotrans-
porter in BBM. As pointed out by Hamm [27], the proximal
luminal uptake of citrate by BBM increases with decreasing pH
of luminal fluid. It should thus be considered that lowering the
pH of proximal tubular fluid, due to the increased Na-H
exchange rate (Table 4), might be an additional factor favoring
Table 3B. Effect of direct addition of 1 mas Li upon Na-gradient-
dependent uptake of [14C]-citrate and [14C]-succinate by BBMV
prepared from normal control rats
Control
Time
mm
(no
addition)
With 1
m Li %
Na-citrate
Exp #1 1
120
212 2
126±5
122 2b
116±8
(—42.4%)
Exp #2 1
120
194 6
125±6
112 4b
121±6
(—42.2%)
Na-succinate
Exp #1 0.25
120
152 2
104±3
125 7b
91±2
(—18%)
Exp #2 0.25
120
244 4
105±2
202 3b
104±2
(—17%)
a Mean SEM of quadruplicatesb Values significantly different from control (1-test)
proximal citrate reabsorption in Li-rats. However, renal han-
dling and metabolism of citrate is very complex [27], and
interpretations surmised here are only hypothetical.
Which biochemical changes of BBM from Li-rats are the
basis of the observed functional differences also remain to be
determined. In this connection, we would like to point out that
Li is a potent inhibitor of myo-inositol-1-phosphatase, one of
the key enzymes in the phosphoinositide cycle [281, and it was
reported that administration of Li to rats enhances many-fold
the content of myo-inositol-1-phosphate content in the kidney
[29]. In view of such findings, prolonged inhibition of myo-
inositol-l-phosphatase might possibly cause an alteration of
phosphoinositide metabolism in BBM which might, by a yet
unknown mechanism, increase the Na-citrate and Na-succi-
nate cotransporter activities as well as the Na-H antiporter
(Fig. 1).
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Table 4. Effect of chronic lithium treatment of rats (Li-rats) on the
rate of the amiloride-sensitive Na-H antiport across renal BBM in
the presence of proton gradient (pH1 <pH0)
Study A
22Na uptake pmol/mg protein
lOsec 20sec 30sec 110 mm
Controls
— Amiloride
+ Amiloride
Amiloride-sensitive
Li-rats
— Amiloride
÷ Amiloride
Amiloride-sensitive
360 10
138 14
222 7
436 52
141 16264 l2
476 35 628 16 1137 14
245 13 290 12 1251 76
235 22 338 6
602 2 743 4Ø 1288 56
291 10 365 21 1522 66311 9 383 9
Study B
22Na uptake pmol/mg protein
15 sec 90 sec
Controls
— Amiloride
+ Amiloride
Amiloride-sensitive
Li-treated
—Amiloride
+ Amiloride
Amiloride-sensitive
208 26 665 115
129 22 693 148
80 12
227 26 651 122
104 17 647 132
124 14 —
Data are mean SEM of 3 experiments. Details are in Methods.
a Significantly different from corresponding control value (P < 0.05;
paired t-test)
In conclusion, we stress that the model of chronic oral
administration of Li to rats was designed [2, 12, 13, 15, 16] to
closely resemble the therapeutic regimen in the clinical practice
and to minimize toxic renal effects of Li. Yet, even in this model
we detected specific alterations in the function of Na-cotrans-
porters in proximal tubular BBM without any changes in
microscopic cellular morphology [14]. Also, functional external
manifestations of these changes in overall renal excretory
parameters are certainly less obvious than the dramatic poly-
uric syndrome due to Li actions on distal nephron [1, 2].
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